News and Press Releases
Bespak achieves sustainability milestone with first life cycle assessment for pressurised Metered Dose Inhaler valve
1 May 2025, Holmes Chapel, UK — Bespak, a specialist inhalation contract development and manufacturing organisation (CDMO), today announced that it has completed its first life cycle assessment (LCA) for...
Category:
Posted: May 1, 2025
Domain Therapeutics Presents Novel Data Addressing Key Challenges in Oncology at AACR 2025
Phase I clinical results of DT-9081, an EP4 receptor antagonist, allowed selection of recommended Phase II dose (RP2D) for further development in solid tumors Preclinical data of DT-7012 position this...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 30, 2025
PARC D'INNOVATION 220 Boulevard Gonthier D'Andernach 67400 Strasbourg - Illkirch - France
Leqembi ▼ (lecanemab) proposed Marketing Authorisation Variation for monthly intravenous maintenance dosing for the treatment of early Alzheimer’s disease in the UK is validated for evaluation by the MHRA
Proposed intravenous maintenance dosing application to reduce lecanemab infusion frequency from every two weeks to every four weeks for eligible adult UK patients after initial 18 months of treatment The...
Category: Other, Pharmaceutical
Posted: April 30, 2025
Iksuda to present growing ADC pipeline at AACR
Introduces the ProAlk payload series to address the growing challenge of ADC sequencing IKS04 to enter clinical development for gastrointestinal cancers by end of 2025 PermaLink offers stable and scalable...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 25, 2025
CN Bio and Pharmaron establish long-term strategic partnership to develop OOC technologies on a global R&D platform
Partnership to validate and promote the application of CN Bio’s PhysioMimix technology, with future opportunities for novel application and assay development 24 April 2025 -- Cambridge, UK -- CN Bio,...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: April 24, 2025
PCI Pharma Services to Acquire US-based Aseptic Fill-Finish CDMO Ajinomoto Althea
Acquisition creates a world-class large-scale manufacturing hub in San Diego region with state-of-the-art aseptic facilities for prefilled syringes, cartridges and high potent formulations such as ADCs, complementing existing global sterile...
Category: Logistics, Manufacturing and Packing, Pharmaceutical
Posted: April 24, 2025
Bioxodes announces positive Phase 2a interim data for BIOX-101 in intracerebral hemorrhagic stroke patients
Primary endpoint met, no drug-related serious adverse events Positive hematoma and edema volume evolution Recruitment stopped early due to positive exploratory and efficacy outcomes Preparations underway to initiate Phase 2b...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 24, 2025
Mosaic Therapeutics in-licenses two clinical-stage oncology programs from Astex Pharmaceuticals for development as proprietary combination therapies
In-licensing transforms Mosaic from a research and platform company to a clinical-stage oncology business Mosaic will develop proprietary, targeted combination products, supported by proprietary biomarkers, to realise the full potential...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: April 24, 2025
Mosaic Therapeutics Wellcome Genome Campus Cambridge CB10 1DR
Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types
Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital™ PCR technology 23 April 2025 -- Colorado,...
Category: BioManufacturing, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2025
Liverpool City Region set to become global powerhouse in new front for fighting disease and driving wellbeing
23 April 2025 -- Liverpool, UK -- Liverpool City Region is set to become a global powerhouse in a new front to tackle deadly diseases and improve wellbeing. More than...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2025
Landmark BioVentures and G.CLIPS Biotech forge strategic alliance to address critical gaps in drug target engagement
Partnership brings into sharper focus need to integrate target engagement and candidate profiling solutions to optimize drug development process and increase likelihood of success23 April 2025 -- Basel, Switzerland, and...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2025
Pharming receives positive recommendation from NICE for Joenja▼(leniolisib) as a treatment for APDS
Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older with activated...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2025
Pharming Group N.V. Vondellaan 47 2332 AA Leiden The Netherlands
Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers
23 April 2025 -- Ingelheim, Germany and Amsterdam, the Netherlands -- Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2025
EsoCap to Present Key Phase II Results on Novel Drug Delivery System in Eosinophilic Esophagitis at DDW 2025
New insights on safety, adherence, and patient satisfaction with ESO-101 to be presented on May 3, 2025, at DDW 2025 ESO-101 features EsoCap’s proprietary drug delivery technology to enable localized...
Category: Biotechnology, Clinical Trials, Drug Delivery, Drug Discovery, Pharmaceutical
Posted: April 22, 2025
Novadip reports key nonclinical and interim clinical data for NVDX3, its off-the-shelf allogenic product,in spine fusion
NVDX3 elicited bone formation as early as 12 weeks and functional fusion by 26 weeks in ovine posterolateral fusion (PLF) model In phase 1b/2a clinical trial, early bone fusion was...
Category: Biotechnology, Clinical Trials, Other
Posted: April 22, 2025
